UNMET NEED
Radiopharmaceutical therapy (RPT) is an emerging cancer treatment modality in which tumor-targeting molecules are used to deliver radioactive atoms thereby irradiating tumors preferentially over normal organs. Therefore, precision medicine dosimetry is required so that patients are administered the appropriate amount of the RPT for safe and effective treatment.
PROBLEM SOLVED
Dosimetry is required by the FDA as part of phase 1 dose escalation studies. Dosimetry data that is trusted by the FDA is essential in securing rapid regulatory approval. This group’s software reduces time to approval for alpha-emitter RPT drugs by:
TECHNICAL DETAILS
The group’s technology implements precision medicine dosimetry using three steps. In the first, proprietary methods quantify the radioactive distribution from pre-treatment images for dose calculations. Secondly, a dose-map is produced using a patient’s anatomy and activity distribution. Lastly, radiobiological models predict tumor response and normal organ toxicity to calculate a patient-specific administered activity.
